IRELAND - Roche et al. invest additional EUR 3.3m into Opsona

Dublin-based Opsona was formed in 2004 by three immunologists of Trinity College Dublin. The company focuses on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, such as rheumatoid arthritis, lupus and solid organ transplant rejection. In particular, the business develops drugs that modulate the innate immune system and its signaling, specifically toll-like receptors (TLR).

The funding will be used to further expand the company's clinical development pipeline by supporting the advancement of clinical trials. It will also be used to improve Opsona's capability to clinically evaluate novel compounds for in-licensing aimed at treating autoimmune and inflammatory diseases.

Opsona first received funding in 2005, with a €6.25m investment from Seroba BioVentures and Inventages Venture Capital.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland